Anthony Tanoto Tan, Fanping Meng, Jiehua Jin, Ji‐Yuan Zhang, Si‐Yu Wang, Lei Shi, Ming Shi, Yuanyuan Li, Yunbo Xie, Li‐Min Liu, Chun‐Bao Zhou, Alicia Chua, Zi Zong Ho, Junqing Luan, Jinfang Zhao, Jing Li, Lu‐En Wai, Sarene Koh, Tingting Wang, Antonio Bertoletti, Fu‐sheng Wang – 20 December 2021 – The application of hepatitis B virus (HBV)–T‐cell receptor (TCR) T‐cell immunotherapy in patients with HBV‐related hepatocellular carcinoma (HBV‐HCC) has been apathetic, as the expression of HBV antigens by both normal HBV‐infected hepatocytes and HCC cells with HBV‐DNA integration increases the ri